

Company

RaQualia Pharma Inc.




Presenter

Shuzo Watanabe



RaQualia Business Model

- Revenue from research collaboration activities with pharmaceutical companies and/or academia
- Open innovation with academia and pharmaceutical companies from discovery stage



Required Partner:

- Pharmaceutical Companies
- Academia
- Bio Venture

Staff

Toshiyuki
Saito



Taku
Sato



Yoriko
Miyake



Research Collaboration

Title	Description
Drug discovery research capability	Experienced researchers at global pharmaceutical companies Maximize the infrastructure that it in the highest class among biotechnology venture companies in Japan and aim to create development compounds
Ion Channel Research	RaQualia has broad and deep experiences in cell-based assay development, HTS execution, electrophysiology from ion channel targets
Collaboration with Academia	Capitalize on the collaboration with academia and accelerate the drug discovery research

Licensing Rights for Development and Commercialization

Program	Compound Code	Target Indication	Stage					Open Territory
			Discovery	Pre-Clinical	P 1	P 2	P 3	
Potassium-Competitive Acid Blocker	RQ-00000004	GERD (RE/NERD)	○	○	●			Japan, US & EU (except East European Countries)
5-HT ₄ Partial Agonist	RQ-00000010	Gastroparesis, Functional Dyspepsia, Chronic Constipation	○	○	●			Japan
5-HT _{2B} Antagonist	RQ-00310941	D-IBS, IBD-remission Stage Symptoms	○	○	●			Japan
1,3-β-D-glucan Synthesis Inhibitor	Anidulafungin RQ-00000001	Candida Infections	○	●	○			Japan
Cell Wall Peptidoglycan Synthesis Inhibitor	Dalbavancin RQ-00000002	MRSA Infections	○	●	○			Japan
Motilin Receptor Agonist	RQ-00201894	Gastroparesis, Functional Dyspepsia, Post-operative Ileus	○	●				WW
Ghrelin Receptor Agonist	RQ-00433412	Cancer-related Anorexia/ Cachexia Syndrome	●	○				WW
TRPM8 Blocker	RQ-00434739	Neuropathic Pain (Chemotherapy-induced Cold Allodynia)	●	○				WW